Under this deal, Merck, known as MSD outside of the United States and Canada, will select Veeva products for industry-specific software and data.
Merck, known as MSD outside of the United States, and Veeva Systems, a provider of cloud systems for the life sciences industry, announced a ten-year strategic partnership agreement on Nov. 1, 2022. Under the agreement, which builds on an existing 12-year partnership between the two companies, Merck will take a “Veeva-first approach” to new industry-specific software and data. Veeva will provide Merck with a strategic pricing approach and allow Merck input into their product roadmap.
“I am excited to see our partnership with Merck evolve to this strategic level,” said Peter Gassner, CEO, Veeva, in a company press release. “Our teams share a common passion for the industry and an understanding of strategic partnership. I look forward to seeing what we create together over the coming years.”
“Transforming our digital, data, and analytics capabilities is integral to enabling our global colleagues to deliver on our purpose of using the power of leading-edge science to save and improve lives around the world,” said Robert M. Davis, CEO and president, Merck, in the release. “Our strategic partnership with Veeva expands our capacity to leverage innovative technology and enhances our ability to deliver value to patients and all our stakeholders—this is key to how we measure success.”
Source: Veeva
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.